secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001378325-25-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision Q2 revenue $3.3M (+17% YoY); IPO closes raising $23.4M
------------------------------------------------------------------

- Revenue $3.3M, up 17% YoY, driven by higher CapsoCam Plus capsule sales.
- Gross profit $1.8M (55% margin) vs. $1.6M (56%) in Q2 2024.
- Operating expenses $6.5M, down $0.4M from prior year due to reduced clinical trial costs.
- Closed IPO on July 3, 2025, net proceeds of $23.4M; cash was $1.1M at June 30.
- Filed 510(k) for CapsoCam Colon in June 2025; AI module addition targeted for FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832525000008/0001378325-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832525000008/cv-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001378325-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer